
NASDAQHealthcareDrug Manufacturers - General
أحدث البيانات المتاحة
7.46 US$
+0.05 US$ · +0.67%
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
الإغلاق السابق
7.46 US$
+0.05 US$ · +0.67%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
نطاق اليوم
السعر الحالي 7.46 US$
نطاق 52 أسبوعًا
السعر الحالي 7.46 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
90
قيمة جذابة جدًا
المشاعر
59
مختلط
المخاطر
43
مخاطر أعلى من المعتاد
الزخم
32
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
نطاق اليوم
السعر الحالي 7.46 US$
نطاق 52 أسبوعًا
السعر الحالي 7.46 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (EUR) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 7.23 مليار EUR | 7.21 مليار EUR | 6.59 مليار EUR | 6.06 مليار EUR | 4.93 مليار EUR |
| تكلفة البضاعة المباعة | 4.65 مليار EUR | 4.42 مليار EUR | 4.11 مليار EUR | 3.85 مليار EUR | 2.97 مليار EUR |
| الربح الإجمالي | 2.58 مليار EUR | 2.79 مليار EUR | 2.48 مليار EUR | 2.21 مليار EUR | 1.96 مليار EUR |
| البحث والتطوير | 358.28 مليون EUR | 384.04 مليون EUR | 395.28 مليون EUR | 361.14 مليون EUR | 354.88 مليون EUR |
| مصاريف البيع والمصاريف العمومية والإدارية | 1.02 مليار EUR | 1.14 مليار EUR | 1.27 مليار EUR | 1.11 مليار EUR | 1.06 مليار EUR |
| نفقات التشغيل | 1.39 مليار EUR | 1.6 مليار EUR | 1.7 مليار EUR | 1.43 مليار EUR | 1.37 مليار EUR |
| دخل الفوائد | 32.66 مليون EUR | 48.05 مليون EUR | 62.43 مليون EUR | 33.86 مليون EUR | 11.55 مليون EUR |
| مصاريف الفوائد | 600.33 مليون EUR | 773.16 مليون EUR | 516.06 مليون EUR | 444.54 مليون EUR | 233.81 مليون EUR |
| الاستهلاك والإطفاء | 432.24 مليون EUR | 437.9 مليون EUR | 446.42 مليون EUR | 410.98 مليون EUR | 359.77 مليون EUR |
| الدخل التشغيلي | 1.19 مليار EUR | 1.19 مليار EUR | 782.32 مليون EUR | 782.44 مليون EUR | 595.06 مليون EUR |
| صافي الدخل | 386.13 مليون EUR | 156.92 مليون EUR | 42.32 مليون EUR | 185.04 مليون EUR | 188.73 مليون EUR |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Biotechnology ETFIBB13.34 مليون0.13%10.28 مليار USD0.44%206.49 US$+3.00%
Brandes International ETFBINV6.87 مليون1.30%528.25 مليون USD0.70%43.36 US$+0.60%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.61 مليون0.10%2.61 مليار USD0.20%66.35 US$+1.13%
Brandes U.S. Small-Mid Cap Value ETFBSMC2.57 مليون1.53%167.59 مليون USD0.70%38.10 US$-0.32%
State Street SPDR Portfolio Developed World ex-US ETFSPDW2.31 مليون0.01%40.46 مليار USD0.03%49.98 US$+0.64%
Capital Group International Core Equity ETFCGIC894.48 ألف0.04%2.56 مليار USD0.54%35.74 US$+0.62%
ActivePassive International Equity ETFAPIE210.89 ألف0.02%1.13 مليار USD0.45%38.56 US$+0.65%
Invesco NASDAQ Future Gen 200 ETFQQQS115.14 ألف0.51%22.45 مليون USD0.20%42.145 US$+1.39%
iShares Biotechnology ETFIBB
Brandes International ETFBINV
State Street SPDR S&P Kensho New Economies Composite ETFKOMP
Brandes U.S. Small-Mid Cap Value ETFBSMC
State Street SPDR Portfolio Developed World ex-US ETFSPDW
Capital Group International Core Equity ETFCGIC
ActivePassive International Equity ETFAPIE
Invesco NASDAQ Future Gen 200 ETFQQQSالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.